Literature DB >> 30083703

Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome.

Roos M van der Vuurst de Vries1, Julia Y Mescheriakova1, Yu Yi M Wong1, Tessel F Runia1, Naghmeh Jafari2, Johnny P Samijn3, Janet W K de Beukelaar4, Beatrijs H A Wokke1, Theodora A M Siepman1, Rogier Q Hintzen1.   

Abstract

Importance: In 2017, the International Panel on Diagnosis of Multiple Sclerosis revised the McDonald 2010 criteria for the diagnosis of multiple sclerosis (MS). The new criteria are easier to apply and could lead to more and earlier diagnoses. It is important to validate these criteria globally for their accuracy in clinical practice. Objective: To evaluate the diagnostic accuracy of the 2017 criteria vs the 2010 criteria in prediction of clinically definite MS in patients with a typical clinically isolated syndrome (CIS). Design, Setting and Patients: A total of 251 patients at Erasmus MC, Rotterdam, the Netherlands, in collaboration with several regional hospitals, fulfilled the inclusion criteria. Thirteen patients received another diagnosis early in the diagnostic process and therefore were excluded from the analyses. Nine patients with CIS declined to participate in the study. This left 229 patients who were included between March 2006 and August 2016 in this prospective CIS cohort. Patients underwent a baseline magnetic resonance imaging scan within 3 months after onset of symptoms and, if clinically required, a lumbar puncture was performed. Data were analyzed between December 2017 and January 2018. Main Outcomes and Measures: Sensitivity, specificity, accuracy, and positive and negative predictive value were calculated after 1, 3, and 5 years for the 2017 vs the 2010 criteria.
Results: Among the 229 patients with CIS, 167 were women (73%), and the mean (SD) age was 33.5 (8.2) years. One hundred thirteen patients (49%) were diagnosed as having CDMS during a mean (SD) follow-up time of 65.3 (30.9) months. Sensitivity for the 2017 criteria was higher than for the 2010 criteria (68%; 95% CI, 57%-77% vs 36%; 95% CI, 27%-47%; P < .001), but specificity was lower (61%; 95% CI, 50%-71% vs 85%; 95% CI, 76%-92%; P < .001). Using the 2017 criteria, more MS diagnoses could be made at baseline (n = 97 [54%]; 95% CI, 47%-61% vs n = 46 [26%]; 95% CI, 20%-32%; P < .001). In the group with at least 5 years of follow-up, 33% of patients who were diagnosed as having MS using the 2017 criteria did not experience a second attack during follow-up vs 23% when using the 2010 criteria. Conclusions and Relevance: The 2017 revised McDonald criteria are associated with greater sensitivity but less specificity for a second attack than the previous 2010 criteria. The tradeoff is that it leads to a higher number of MS diagnoses in patients with a less active disease course.

Entities:  

Mesh:

Year:  2018        PMID: 30083703      PMCID: PMC6248116          DOI: 10.1001/jamaneurol.2018.2160

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  28 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Authors:  Massimo Filippi; Paolo Preziosa; Alessandro Meani; Olga Ciccarelli; Sarlota Mesaros; Alex Rovira; Jette Frederiksen; Christian Enzinger; Frederik Barkhof; Claudio Gasperini; Wallace Brownlee; Jelena Drulovic; Xavier Montalban; Stig P Cramer; Alexander Pichler; Marloes Hagens; Serena Ruggieri; Vittorio Martinelli; Katherine Miszkiel; Mar Tintorè; Giancarlo Comi; Iris Dekker; Bernard Uitdehaag; Irena Dujmovic-Basuroski; Maria A Rocca
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

3.  A clinico-pathoanatomical study of multiple sclerosis diagnosis.

Authors:  T Engell
Journal:  Acta Neurol Scand       Date:  1988-07       Impact factor: 3.209

4.  Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes.

Authors:  M Gómez-Moreno; M Díaz-Sánchez; A Ramos-González
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

5.  Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes.

Authors:  T F Runia; N Jafari; R Q Hintzen
Journal:  Eur J Neurol       Date:  2013-07-30       Impact factor: 6.089

6.  Longitudinal follow-up of "benign" multiple sclerosis at 20 years.

Authors:  Ana-Luiza Sayao; Virginia Devonshire; Helen Tremlett
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

7.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

8.  Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?

Authors:  S C Rosenkranz; B Kaulen; A Neuhaus; S Siemonsen; S Köpke; M Daumer; J-P Stellmann; C Heesen
Journal:  Eur J Neurol       Date:  2017-12-02       Impact factor: 6.089

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  10 in total

1.  The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.

Authors:  Pietro Maggi; Martina Absinta; Pascal Sati; Gaetano Perrotta; Luca Massacesi; Bernard Dachy; Caroline Pot; Reto Meuli; Daniel S Reich; Massimo Filippi; Renaud Du Pasquier; Marie Théaudin
Journal:  Mult Scler       Date:  2019-09-19       Impact factor: 6.312

Review 2.  Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.

Authors:  Mohamed AlJumah; Mona Marwan Alkhawajah; Shireen Qureshi; Ibtisam Al-Thubaiti; Omar Ayoub; Saeed A Bohlega; Areej Bushnag; Edward Cupler; Abdulkader Daif; Ahmed El Boghdady; Ahmed Hassan; Yaser Al Malik; Jameelah Saeedi; Fawzia Al-Shamrany; Eslam Shosha; Peter Rieckmann
Journal:  Neurol Ther       Date:  2020-02-13

3.  Conversion of clinically isolated syndrome to multiple sclerosis: a prospective multi-center study in Eastern India.

Authors:  T K Banerjee; M Saha; E Ghosh; A Hazra; A Das; D Choudhury; S Ojha; A Haldar; A Mukherjee; S S Nandi; A Ghosh; A Mukherjee; A Chatterjee; A Datta; S Purakayastha
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-05-13

Review 4.  Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Authors:  Massimo Filippi; Paolo Preziosa; Brenda L Banwell; Frederik Barkhof; Olga Ciccarelli; Nicola De Stefano; Jeroen J G Geurts; Friedemann Paul; Daniel S Reich; Ahmed T Toosy; Anthony Traboulsee; Mike P Wattjes; Tarek A Yousry; Achim Gass; Catherine Lubetzki; Brian G Weinshenker; Maria A Rocca
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

5.  Application of the 2017 McDonald criteria in a Chinese population with clinically isolated syndrome.

Authors:  Yang Zheng; Chun-Hong Shen; Sa Wang; Fan Yang; Meng-Ting Cai; Wei Fang; Yin-Xi Zhang; Mei-Ping Ding
Journal:  Ther Adv Neurol Disord       Date:  2020-01-20       Impact factor: 6.570

6.  Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis.

Authors:  Krista D DiSano; Francesca Gilli; Andrew R Pachner
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-12-16

7.  Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; David Leppert; Jens Kuhle; Daniel C Anthony
Journal:  Brain Commun       Date:  2021-04-19

8.  Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; Jens Kuhle; David Leppert; Daniel C Anthony
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

9.  Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.

Authors:  Andrew J Solomon; Marwa Kaisey; Stephen C Krieger; Salim Chahin; Robert T Naismith; Sarah M Weinstein; Russell T Shinohara; Brian G Weinshenker
Journal:  Mult Scler       Date:  2021-10-06       Impact factor: 5.855

10.  IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis.

Authors:  Yang Zheng; Meng-Ting Cai; Fan Yang; Ji-Ping Zhou; Wei Fang; Chun-Hong Shen; Yin-Xi Zhang; Mei-Ping Ding
Journal:  Front Immunol       Date:  2020-08-20       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.